Compare Amphastar Pharmaceuticals Inc (AMPH) vs Tesla, Inc. (TSLA) Price & Performance

AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.

The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.

Tesla (TSLA) trades at $407.74, up 0.29% today, with a neutral technical signal and key support at $396. The stock shows elevated valuation multiples (P/E 374.09, P/S 14.72) amid declining profitability, with net income margin falling to 3.95% in 2025. Recent Q1 2026 earnings beat expectations, but revenue growth has stalled. News highlights focus on Tesla's pivot to AI, robotics, and regulatory approval for self-driving software in Europe (Reuters, 2026-04-10).

Outlook remains bifurcated: long-term optimism around autonomy and energy growth contrasts with near-term EV demand pressures and high valuation risks. Analyst consensus is mixed with a $436.41 price target, but competitive and execution risks persist. Cash flow stability improved with net positive $579M in 2025, though investing outflows remain high.